A Regional Observational Study on COVID-19-Associated Pulmonary Aspergillosis (CAPA) within Intensive Care Unit: Trying to Break the Mold.
Aspergillus
COVID-19
COVID-19-associated pulmonary aspergillosis
antifungal agents
aspergillosis
bronchoalveolar lavage fluid
bronchopulmonary
fungal infection
intensive care unit
pulmonary
Journal
Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827
Informations de publication
Date de publication:
30 Nov 2022
30 Nov 2022
Historique:
received:
03
11
2022
revised:
24
11
2022
accepted:
26
11
2022
entrez:
22
12
2022
pubmed:
23
12
2022
medline:
23
12
2022
Statut:
epublish
Résumé
The reported incidence of COVID-19-associated pulmonary aspergillosis (CAPA) ranges between 2.4% and 35% in intensive care unit (ICU) patients, and awareness in the medical community is rising. We performed a regional retrospective observational study including patients diagnosed with CAPA defined according to the Modified AspICU Dutch/Belgian Mycosis Study Group and CAPA-EECMM, from five different ICUs, admitted between March, 2020 and September, 2021. Forty-five patients were included. The median age was 64 (IQR 60-72), mostly (73%) males. At ICU admission, the median Charlson comorbidity index was 3 (2-5), and the simplified acute physiology score (SAPS)-II score was 42 (31-56). The main underlying diseases were hypertension (46%), diabetes (36%) and pulmonary diseases (15%). CAPA was diagnosed within a median of 17 days (IQR 10-21.75) after symptoms onset and 9 days (IQR 3-11) after ICU admission. The overall 28-day mortality rate was 58%, and at univariate analysis, it was significantly associated with older age (
Identifiants
pubmed: 36547597
pii: jof8121264
doi: 10.3390/jof8121264
pmc: PMC9785727
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Turk J Anaesthesiol Reanim. 2016 Dec;44(6):279-282
pubmed: 28058136
Int Immunopharmacol. 2021 Dec;101(Pt A):108200
pubmed: 34607231
Mycopathologia. 2021 Jun;186(3):341-354
pubmed: 34089172
J Fungi (Basel). 2021 Dec 11;7(12):
pubmed: 34947049
Crit Care Explor. 2022 May 09;4(5):e0696
pubmed: 35558738
Clin Infect Dis. 2021 Oct 5;73(7):e1634-e1644
pubmed: 32860682
Front Med (Lausanne). 2021 Nov 16;8:753659
pubmed: 34869450
Infection. 2022 Feb;50(1):43-56
pubmed: 34570355
Int J Mol Sci. 2022 Mar 17;23(6):
pubmed: 35328649
Intensive Care Med. 2020 Aug;46(8):1524-1535
pubmed: 32572532
Open Forum Infect Dis. 2022 Mar 03;9(5):ofac081
pubmed: 35386295
Clin Infect Dis. 2021 Mar 12;72(Suppl 2):S121-S127
pubmed: 33709127
Pathogens. 2021 Oct 22;10(11):
pubmed: 34832526
Intensive Care Med. 2021 Nov;47(11):1339-1340
pubmed: 34468820
Clin Microbiol Infect. 2022 Jul;28(7):920-927
pubmed: 35150878
Expert Rev Respir Med. 2021 Aug;15(8):985-992
pubmed: 33962524
Infect Drug Resist. 2020 Oct 12;13:3525-3534
pubmed: 33116671
Front Immunol. 2022 Mar 24;13:835104
pubmed: 35401519
Intern Emerg Med. 2021 Sep;16(6):1619-1627
pubmed: 33751395
Lancet Infect Dis. 2021 Jun;21(6):e149-e162
pubmed: 33333012
Crit Care. 2021 Sep 15;25(1):335
pubmed: 34526087
Lancet Microbe. 2020 Jun;1(2):e53-e55
pubmed: 32835328
Intensive Care Med. 2022 Mar;48(3):360-361
pubmed: 34940907
Future Microbiol. 2021 Mar;16:317-322
pubmed: 33709775
J Clin Microbiol. 2022 Apr 20;60(4):e0229821
pubmed: 35321555
Open Forum Infect Dis. 2021 Oct 02;8(11):ofab478
pubmed: 34805426
Mycoses. 2021 Sep;64(9):980-988
pubmed: 34143533
Turk J Anaesthesiol Reanim. 2016 Dec;44(6):283-284
pubmed: 28058137
Mycoses. 2021 Sep;64(9):993-1001
pubmed: 33896063
BMJ. 2021 Mar 10;372:n436
pubmed: 33692022
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Ann Intensive Care. 2021 Sep 15;11(1):136
pubmed: 34524562